According to Codexis
's latest financial reports the company has $65.11 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $65.11 M | -42.87% |
2022-12-31 | $0.11 B | -2.41% |
2021-12-31 | $0.11 B | -22.2% |
2020-12-31 | $0.15 B | 65.88% |
2019-12-31 | $90.49 M | 70.63% |
2018-12-31 | $53.03 M | 69.89% |
2017-12-31 | $31.21 M | 62.26% |
2016-12-31 | $19.24 M | -17.33% |
2015-12-31 | $23.27 M | -12.13% |
2014-12-31 | $26.48 M | 5.38% |
2013-12-31 | $25.13 M | -44.79% |
2012-12-31 | $45.52 M | -14.87% |
2011-12-31 | $53.48 M | -26.13% |
2010-12-31 | $72.39 M | 30.3% |
2009-12-31 | $55.56 M | 49.64% |
2008-12-31 | $37.13 M | -55.83% |
2007-12-31 | $84.07 M | 160.71% |
2006-12-31 | $32.24 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $12.69 B | 19,388.30% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | 10,792.87% | ๐บ๐ธ USA |
Dupont De Nemours DD | $2.39 B | 3,573.44% | ๐บ๐ธ USA |
Balchem BCPC | $64.44 M | -1.03% | ๐บ๐ธ USA |